<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The INK4A/ARF locus yields two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors, p16INK4A and p14ARF, and is frequently deleted in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We studied their <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions in 41 hematopoietic cell lines and in 137 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>; we used a quantitative reverse transcription-PCR assay </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> peripheral bloods, bone marrow and lymph nodes expressed little or undetectable p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNAs</z:chebi>, which were readily detected in 12 and 17 of 41 cell lines, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> frequently lacked p16INK4A expression (60/137) and lost p14ARF expression less frequently (19/137, 13.9%) </plain></SENT>
<SENT sid="4" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> patients without p14ARF expression lacked p16INK4A expression, which may correspond to deletions of the INK4A/ARF locus </plain></SENT>
<SENT sid="5" pm="."><plain>Undetectable p16INK4A expression with p14ARF expression in 41 patients may correspond to p16INK4A promoter methylation or to <z:mpath ids='MPATH_458'>normal</z:mpath> expression status of the p16INK4A gene </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), <z:mp ids='MP_0009440'>myeloma</z:mp> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) expressed p14ARF while nine of 23 patients with diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) lost p14ARF expression </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with ALL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> expressed abundant p16INK4A <z:chebi fb="2" ids="33699">mRNAs</z:chebi> more frequently than patients with other diseases (12/33 vs 6/104, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with FL and high p14ARF expression had a significantly shorter survival time while survival for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and increased p14ARF expression tended to be longer </plain></SENT>
<SENT sid="9" pm="."><plain>These observations indicate that p16INK4A and p14ARF expression is differentially affected among hemato- logical <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and that not only inactivation but also increased expression may have clinical significance </plain></SENT>
</text></document>